Comparative Pharmacology
Head-to-head clinical analysis: BRISTACYCLINE versus DORYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTACYCLINE versus DORYX.
BRISTACYCLINE vs DORYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTACYCLINE is a tetracycline antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
250 mg orally every 6 hours for 7-14 days.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
None Documented
None Documented
6-12 hours (terminal). In renal impairment, half-life extends up to 24-48 hours; dose adjustment required for CrCl <30 mL/min.
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
Renal (40-60% unchanged), fecal (20-30%, primarily as inactive metabolites). Biliary excretion contributes minimally (<5%).
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic